502 filings
Page 8 of 26
8-K
hcukcvns
1 Feb 11
Other Events
12:00am
8-K
x5e46h
10 Jan 11
Other Events
12:00am
8-K
liz30ivg kflrw7vj4s
10 Jan 11
NPS Pharmaceuticals Announces Completion of Treatment Phase in STEPS Registration Study of GATTEX in Short Bowel Syndrome
12:00am
8-K
k7qmi wnxw
18 Nov 10
NPS Pharmaceuticals Appoints Pedro Granadillo to Board of Directors
12:00am
EFFECT
1wgfouo4fssyxt0u8
10 Nov 10
Notice of effectiveness
12:00am
8-K
x9zsfxtg
2 Nov 10
NPS Pharmaceuticals Reports Third Quarter 2010 Financial Results and Two Phase 3 Development Programs on Track with Stated Timelines
12:00am
UPLOAD
wcz4sm gjgzz
15 Oct 10
Letter from SEC
12:00am
8-K
qv5fob691tj8mnmse7
21 Sep 10
NPS Pharmaceuticals Announces Closing of $47.5 Million Public Offering of Common Stock and Exercise of Overallotment Option
12:00am
8-K
zr8 ln5e8
16 Sep 10
Entry into a Material Definitive Agreement
12:00am
424B5
tw81wgnbdeivu
16 Sep 10
Prospectus supplement for primary offering
12:00am
S-3MEF
i6tzo
15 Sep 10
Registration of additional securities for an S-3
12:00am
424B5
owwihog 7m3
15 Sep 10
Prospectus supplement for primary offering
12:00am
CORRESP
rn13wweqs b48pc
14 Sep 10
Correspondence with SEC
12:00am
UPLOAD
zog0s1mqv30pp4wl0y
31 Aug 10
Letter from SEC
12:00am
S-8
f55n3kb7l
4 Aug 10
Registration of securities for employees
12:00am
8-K
yhodu5q938
4 Aug 10
NPS Pharmaceuticals Reports Second Quarter 2010 Financial Results and Two Phase 3 Registration Programs on Track with Stated Timelines
12:00am
8-K
655wgua17nt1
22 Jul 10
NPS Pharmaceuticals Announces Completion of Patient Randomization in Phase 3 STEPS Study of GATTEX® in Short Bowel Syndrome
12:00am